Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.86B | 3.18B | 2.83B | 2.32B | 2.86B | 2.52B |
Gross Profit | 962.40M | 1.06B | 963.40M | 763.80M | 957.30M | 813.30M |
EBITDA | 247.90M | 140.10M | 420.20M | 401.50M | 546.50M | 330.40M |
Net Income | -15.70M | -211.00M | 569.70M | 208.90M | 249.90M | -60.10M |
Balance Sheet | ||||||
Total Assets | 4.68B | 5.24B | 5.55B | 3.87B | 4.01B | 3.99B |
Cash, Cash Equivalents and Short-Term Investments | 169.30M | 199.30M | 242.90M | 232.20M | 446.10M | 302.20M |
Total Debt | 1.75B | 2.06B | 2.10B | 1.31B | 1.32B | 1.67B |
Total Liabilities | 3.32B | 3.78B | 3.88B | 2.76B | 2.78B | 2.91B |
Stockholders Equity | 1.32B | 1.42B | 1.63B | 1.08B | 1.21B | 1.06B |
Cash Flow | ||||||
Free Cash Flow | 112.70M | 137.10M | 137.70M | 140.80M | 488.40M | 318.90M |
Operating Cash Flow | 155.00M | 191.30M | 207.00M | 191.10M | 528.40M | 354.80M |
Investing Cash Flow | 151.40M | 26.80M | -729.90M | -143.40M | 126.00M | -1.30B |
Financing Cash Flow | -347.50M | -227.10M | 693.40M | -244.20M | -523.30M | 854.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Neutral | $1.55B | 26.10 | 9.51% | 1.39% | -0.38% | -44.93% | |
69 Neutral | $2.54B | 45.36 | 8.37% | 0.61% | 9.64% | -24.68% | |
69 Neutral | $1.12B | 21.61 | 13.70% | 1.74% | 2.60% | 51.33% | |
65 Neutral | €10.77B | 24.24 | 6.13% | 2.50% | 4.78% | -14.92% | |
55 Neutral | $1.84B | ― | -1.50% | 3.44% | -7.93% | 91.44% | |
54 Neutral | $1.80B | ― | -28.31% | ― | 14.40% | -662.25% | |
54 Neutral | $2.37B | ― | -21.02% | ― | 20.19% | -12.34% |
On August 11, 2025, Hillenbrand announced its fiscal third-quarter results for the period ending June 30, 2025. The company reported a 24% decrease in revenue to $599 million, primarily due to the divestiture of the MIME business and lower capital equipment volume. Despite these challenges, Hillenbrand achieved $30 million in cost synergies from recent acquisitions and reduced debt by over $300 million through strategic divestitures. The company remains focused on its higher margin, higher growth businesses, although it faces ongoing challenges from macroeconomic conditions and tariffs.
On July 17, 2025, Hillenbrand, Inc. completed an amendment to its €325,000,000 Syndicated L/G Facility Agreement originally dated June 21, 2022. The amendment increases the maximum permitted Leverage Ratio for specific fiscal quarters from June 30, 2025, through March 31, 2027. This adjustment in the leverage ratio reflects Hillenbrand’s strategic financial planning, potentially impacting its financial flexibility and relationships with lenders and financial institutions.
On July 9, 2025, Hillenbrand, Inc. entered into a Fifth Amended and Restated Credit Agreement with JPMorgan Chase Bank and J.P. Morgan SE, among others. The new Credit Agreement revises the previous one from June 8, 2022, reducing the revolving credit facility from $1 billion to $700 million, with an option to increase by $600 million. It includes two term loan facilities: a $175 million U.S. Dollar-denominated term loan and a €240 million Euro-denominated term loan. These facilities aim to refinance existing debts and support general corporate purposes. The agreement includes various covenants and conditions, such as maximum leverage ratios and interest coverage ratios, and allows for extensions of the maturity date. The changes in the credit structure are expected to impact Hillenbrand’s financial flexibility and operational strategies.
Hillenbrand, Inc. announced the departure of Robert VanHimbergen as Chief Financial Officer, effective June 27, 2025, and the appointment of Megan Walke as Interim CFO starting June 28, 2025. Ms. Walke, who has been with the company since 2011, will also continue her roles as Vice President, Corporate Controller, and Chief Accounting Officer. The company is still searching for a permanent CFO replacement, and Ms. Walke has entered into a Change in Control Agreement similar to those of other executive officers.